PB Fintech has delivered another quarter that left little room for doubt on execution, but plenty of debate on valuation. The June-quarter performance reinforced the company’s ability to sustain strong revenue growth, expand profitability and deepen both its insurance and lending franchises.
Q1 Financials Show Sharp Improvement
PB Fintech reported a 91.7% year-on-year (YoY) jump in consolidated net profit to Rs 163 crore in the June quarter of FY27, while revenue rose 40% annually to Rs 1,888 crore. Operating performance improved sharply, with earnings before interest, tax, depreciation and amortisation (EBITDA) increasing to Rs 139 crore from Rs 34 crore a year earlier, while EBITDA margin expanded to 7.4% from 2.5%.
The quarter demonstrated PB Fintech’s strong execution across its core businesses. The debate, however, has shifted beyond earnings, with investors now weighing whether the company’s sustained growth can continue to offset concerns around rich valuations and evolving regulatory risks.
Related: Trump threatens Iran over Strait of Hormuz closure
Brokerage Views on Valuation and Growth
Brokerage houses remain split on the outlook. Macquarie maintained an Outperform rating with a target price of Rs 1,950. The firm noted that growth momentum remains unabated, with strong revenue growth and profitability broadly in line with expectations. It believes the renewal insurance book is beginning to contribute meaningfully, while newer initiatives continue to progress well.
Morgan Stanley, however, maintained an Underweight stance with a target price of Rs 1,215. The firm described the quarter as good, with adjusted EBITDA margins in line and EBITDA beating estimates on stronger revenues. It noted healthy growth in new protection premiums but cautioned that the comparison base becomes more demanding from the third quarter onwards. The firm retained its cautious stance due to expensive valuations and the potential impact of regulatory changes on commissions.
Nomura also maintained a Neutral rating with a target price of Rs 1,590. The firm said the June-quarter performance exceeded estimates by around 10%. It highlighted improving take rates and contribution margins across Policybazaar’s insurance platforms. Nomura noted that Paisabazaar’s core loan disbursals are gaining momentum, with new product launches lined up later this month. The firm stated that regulatory uncertainty remains an important monitorable.
While the company’s execution continues to justify its premium valuation, the market is paying close attention to how these growth engines perform against a backdrop of regulatory scrutiny. If the firm can maintain its profitability trajectory without triggering stricter oversight, the current price levels may prove defensible. However, any regulatory intervention that impacts commission structures or expands the scope of scrutiny could weigh heavily on the stock, regardless of how well the business performs.
